Local News

• Teva to acquire Barr  Teva Pharmaceutical and Barr Pharmaceuticals announced today that they have signed a definitive agreement under which Teva will acquire Barr, the fourth largest generic drug company worldwide. Each share of Barr common stock will be converted into $39.90 in cash and 0.6272 Teva ADRs.
  Barr Pharmaceuticals, Inc. July 18, 2008  
• U.S. cancels test of experimental AIDS vaccine  Federal researchers dropped plans for a large-scale test of an experimental AIDS vaccine developed by the National Institutes of Health - the latest fallout from the failure last September of a similar candidate from drugmaker Merck that may have left some volunteers more vulnerable to HIV.
  San Francisco Chronicle July 18, 2008  Sabin Russell
• Merck to fund U.S. VIOXX(R) product liability resolution program  Merck & Co. said that it is satisfied that the thresholds necessary to trigger funding of the program to resolve state and federal VIOXX myocardial infarction (MI) and ischemic stroke (IS) claims in the United States will be met.
  Merck & Co., Inc. July 17, 2008  
• Genzyme and PTC Therapeutics announce collaboration on small molecule for genetic disease  Genzyme and PTC Therapeutics announced an exclusive global collaboration to develop and commercialize PTC124, PTC's novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations.
  Genzyme Corporation July 17, 2008  
• 3M Health Care and Greystone Pharmaceuticals announce license agreement  3M Health Care and Greystone Pharmaceuticals announce they have entered into an exclusive, worldwide license agreement for wound care products using Greystone's patented PHI technology, a proprietary formulation that aids in the management of hard-to-heal wounds.
  3M July 17, 2008  
• Abbott reports stronger-than-expected sales and earnings growth in second quarter  Abbott announced financial results for the second quarter ended June 30, 2008. Diluted earnings per share, excluding specified items, were $0.84, above Abbott's previously announced guidance range of $0.78 to $0.80, reflecting 21.7 percent growth.
  Abbott July 16, 2008  
• Forty percent of men with ED don't talk to their doctor, survey finds  A new survey reveals that while 82 percent of men with erectile dysfunction (ED) surveyed recognize it as an indicator of other health conditions, such as heart disease and diabetes, nearly 40 percent have never discussed the condition with their doctors.
  Eli Lill and Company July 16, 2008  
• Wyeth and Impax announce final settlement of Effexor XR patent suit  Wyeth and Impax Laboratories announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR antidepressant have been approved by the United States District Court for the District of Delaware.
  Wyeth July 16, 2008  
• FDA moves forward with exempting Phase I drugs from GMPs  More than two years after withdrawing a final rule that would have exempted investigational drugs in Phase I testing from certain good manufacturing practice (GMP) regulations, the FDA is issuing a final rule to do just that.
  FDAnews July 16, 2008  
• FDA Advisory Committee provides opinion of DORIBAX(TM) for hospital-acquired pneumonia  Johnson & Johnson Pharmaceutical Research & Development announced that the FDA's Anti-Infective Drugs Advisory Committee voted in favor of the efficacy and safety data for DORIBAX(TM) for the treatment of hospital-acquired pneumonia, or nosocomial pneumonia, and ventilator-associated pneumonia.
  Johnson & Johnson July 16, 2008  

   (next 10 articles)